Over time, the role of the PD-1/PD-L1 axis in MF and SS has been more solidified, making immune checkpoint inhibitors, particularly PD-1 inhibitors pembrolizumab and nivolumab, a promising approach to therapy. The gene discussed is PDCD1; the disease is synovial sarcoma.